Q702 for the Treatment of Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT06712810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor
Study identification
- NCT ID
- NCT06712810
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 46 participants
Conditions and interventions
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Histiocytic Sarcoma
- Malignant Histiocytosis
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Primary Central Nervous System Lymphoma
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Erdheim-Chester Disease
- Recurrent Fibroblastic Reticular Cell Sarcoma
- Recurrent Follicular Lymphoma
- Recurrent Histiocytic Sarcoma
- Recurrent Interdigitating Dendritic Cell Sarcoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelofibrosis
- Recurrent Rosai-Dorfman-Destombes Disease
- Recurrent Small Lymphocytic Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Erdheim-Chester Disease
- Refractory Fibroblastic Reticular Cell Sarcoma
- Refractory Follicular Lymphoma
- Refractory Histiocytic Sarcoma
- Refractory Interdigitating Dendritic Cell Sarcoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Myelodysplastic Syndrome
- Refractory Myelofibrosis
- Refractory Rosai-Dorfman-Destombes Disease
- Refractory Small Lymphocytic Lymphoma
- Refractory Waldenstrom Macroglobulinemia
- Rosai-Dorfman-Destombes Disease
Interventions
- Axl/Mer/CSF1R Inhibitor Q702 Drug
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Positron Emission Tomography Procedure
- Survey Administration Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2025
- Primary completion
- Sep 14, 2030
- Completion
- Sep 14, 2030
- Last update posted
- Oct 9, 2025
2025 – 2030
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | Recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06712810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06712810 live on ClinicalTrials.gov.